1,071.10
price down icon0.39%   -6.09
 
loading
Lilly Eli Co stock is traded at $1,071.10, with a volume of 738.97K. It is down -0.39% in the last 24 hours and up +4.43% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,077.19
Open:
$1081.75
24h Volume:
738.97K
Relative Volume:
0.22
Market Cap:
$958.27B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.97
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
-3.16%
1M Performance:
+4.43%
6M Performance:
+34.24%
1Y Performance:
+44.05%
1-Day Range:
Value
$1,063.00
$1,084.00
1-Week Range:
Value
$1,058.00
$1,133.95
52-Week Range:
Value
$623.78
$1,133.95

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
47,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
1,070.67 964.11B 59.42B 18.41B 6.44B 20.22
Drug Manufacturers - General icon
JNJ
Johnson Johnson
218.21 514.75B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
219.07 390.15B 59.64B 2.36B 19.68B 1.3253
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
145.40 271.72B 54.45B 14.42B 17.15B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
108.85 268.70B 63.90B 19.05B 13.05B 7.5596

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-07-26 Resumed UBS Buy
Dec-16-25 Upgrade Daiwa Securities Neutral → Buy
Dec-15-25 Reiterated BofA Securities Buy
Dec-15-25 Reiterated Goldman Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-10-25 Upgrade Leerink Partners Market Perform → Outperform
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
11:35 AM

Lilly and NVIDIA unveil $1B co-innovation lab in SF - drugdiscoverytrends.com

11:35 AM
pulisher
11:01 AM

JP Morgan 2026: Eli Lilly’s Continuing GLP-1 Success - Pharmaceutical Executive

11:01 AM
pulisher
10:01 AM

Nvidia and Eli Lilly bet $1 billion on AI-powered drug discovery - Longevity.Technology

10:01 AM
pulisher
09:59 AM

Nvidia, Eli Lilly to Invest USD 1 Billion in AI Co-Innovation Lab for Drug Discovery - TelecomTalk

09:59 AM
pulisher
09:47 AM

BMO Capital reiterates Outperform rating on Eli Lilly stock at $1,200 - Investing.com

09:47 AM
pulisher
09:06 AM

Is It Time to Dump Your Shares of Eli Lilly? - Finviz

09:06 AM
pulisher
07:12 AM

Biogen CEO says at-home Alzheimer’s drug will give edge over Lilly - Investing.com

07:12 AM
pulisher
06:00 AM

Biogen CEO Sees Edge Over Lilly With At-Home Alzheimer’s Drug - Bloomberg.com

06:00 AM
pulisher
02:53 AM

Jim Cramer Calls Nvidia, Eli Lilly Partnership 'Monumental Effort' To 'Speed Up' Critical Drug Creation - Benzinga

02:53 AM
pulisher
02:01 AM

NVIDIA, Lilly Launch AI Lab to Transform Drug Discovery Innovations - filmogaz.com

02:01 AM
pulisher
01:23 AM

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - Investing.com

01:23 AM
pulisher
Jan 13, 2026

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns - MarketBeat

Jan 13, 2026
pulisher
Jan 13, 2026

French Government Shoots Down Rumors Eli Lilly (LLY) Is Planning to Acquire Biotech Firm Abivax - TipRanks

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly CFO: Weight-loss pill could have 20% global penetration - Yahoo Finance UK

Jan 13, 2026
pulisher
Jan 13, 2026

Illumina Announces Alliance Framework with AstraZeneca, Merck, and Eli Lilly and Company - marketscreener.com

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms - TechStock²

Jan 13, 2026
pulisher
Jan 13, 2026

JPM: NVIDIA Launches AI Collaborations with Eli Lilly, Thermo Fisher - Genetic Engineering and Biotechnology News

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? - Finviz

Jan 13, 2026
pulisher
Jan 13, 2026

Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds - Benzinga

Jan 13, 2026
pulisher
Jan 13, 2026

The Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Lam Research and Ampco-Pittsburgh - Yahoo Finance Singapore

Jan 13, 2026
pulisher
Jan 13, 2026

Nvidia Drives 70% Drug‑Discovery Cost Crash; Lilly Bets $1BEli Lilly and Co (NYSE:LLY), NVIDIA (NASDAQ:NVDA) - Benzinga

Jan 13, 2026
pulisher
Jan 13, 2026

Lilly and NVIDIA: a $1bn leap for drug discovery - European Medical Journal

Jan 13, 2026
pulisher
Jan 13, 2026

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? - Yahoo Finance

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly (LLY) Targets Q2 2026 FDA Approval for Obesity Pill - GuruFocus

Jan 13, 2026
pulisher
Jan 13, 2026

What to Expect From Eli Lilly’s Q4 2025 Earnings Report - Barchart.com

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly CFO says obesity pill on track for FDA nod in Q2 - Seeking Alpha

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly and Nividia Commit $1B Over 5 Years for AI-Driven Drug Discovery Lab - AI Insider

Jan 13, 2026
pulisher
Jan 13, 2026

NVIDIA to Invest US$1 Billion in an AI Drug Laboratory with Eli Lilly - Eudaimonia and Co

Jan 13, 2026
pulisher
Jan 13, 2026

Antidepressant Market Is Booming So Rapidly | Eli Lilly and Company, Pfizer Inc., GlaxoSmithKline PLC, AstraZeneca - openPR.com

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup - Chartmill

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly Stock Rises on $1 Billion AI Bet With Nvidia - GuruFocus

Jan 13, 2026
pulisher
Jan 13, 2026

NVIDIA & Eli Lilly: AI Lab a New Dawn for Drug Manufacturing - Manufacturing Digital

Jan 13, 2026
pulisher
Jan 13, 2026

NVIDIA, Lilly launch $1B AI Lab to transform drug discovery - Qazinform

Jan 13, 2026
pulisher
Jan 13, 2026

Eli Lilly and NVIDIA invest in AI-driven pharmaceutical innovation - Digital Watch Observatory

Jan 13, 2026
pulisher
Jan 13, 2026

Nvidia (NVDA) Stock; Gains Slightly on $1B AI Co-Innovation Lab with Eli Lilly - CoinCentral

Jan 13, 2026
pulisher
Jan 13, 2026

NVIDIA, Eli Lilly Launch Physical AI Institute - 조선일보

Jan 13, 2026
pulisher
Jan 13, 2026

Nvidia and Eli Lilly launch joint AI lab to advance drug discovery and manufacturing - digitimes

Jan 13, 2026
pulisher
Jan 13, 2026

Nvidia-Lilly $1B AI Lab To Transform Drug Discovery - Electronics For You BUSINESS

Jan 13, 2026
pulisher
Jan 12, 2026

First-of-Its-Kind AI Drug Discovery Lab: NVIDIA, Eli Lilly Announce $1B Investment at J.P. Morgan Healthcare - geneonline.com

Jan 12, 2026
pulisher
Jan 12, 2026

Nvidia, Eli Lilly plan $1 billion AI laboratory to accelerate drug research - StoryBoard 18

Jan 12, 2026
pulisher
Jan 12, 2026

Risk Recap: Can Eli Lilly and Company weather a recessionWeekly Market Report & Daily Momentum Trading Reports - baoquankhu1.vn

Jan 12, 2026
pulisher
Jan 12, 2026

AI healthcare enters a golden era of development! NVIDIA and Eli Lilly and Co invest in AI-driven drug discovery, while OpenAI acquires healthcare startup Torch. - 富途牛牛

Jan 12, 2026
pulisher
Jan 12, 2026

Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.

Jan 12, 2026
pulisher
Jan 12, 2026

NVIDIA and Eli Lilly and Co are investing in AI-driven pharmaceuticals, with the potential to integrate robotics technology in the future. A new growth pole in the healthcare industry is gradually taking shape. - 富途牛牛

Jan 12, 2026
pulisher
Jan 12, 2026

Nvidia, Lilly to invest up to $1B in new AI medical research lab - SiliconANGLE

Jan 12, 2026
pulisher
Jan 12, 2026

AI-driven drug discovery gets $1 billion boost from Nvidia, Lilly - WISH-TV

Jan 12, 2026
pulisher
Jan 12, 2026

JPM26, Day 1: Lilly, Nvidia expand AI team-up; Takeda R&D head talks lack of deal announcements - Fierce Biotech

Jan 12, 2026
pulisher
Jan 12, 2026

NVIDIA And Lilly Announce Co-Innovation AI Lab To Reinvent Drug Discovery In The Age Of AI - Pulse 2.0

Jan 12, 2026
pulisher
Jan 12, 2026

Nvidia and Eli Lilly to open joint AI lab focused on drug development in South San Francisco - The Business Journals

Jan 12, 2026
pulisher
Jan 12, 2026

Lilly will have supply of new weight loss pill for many countries, exec says - Reuters

Jan 12, 2026
pulisher
Jan 12, 2026

Nvidia, US firm Eli Lilly to launch $1b AI co-innovation lab - Tech in Asia

Jan 12, 2026

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$218.28
price up icon 2.20%
$219.25
price down icon 0.42%
drug_manufacturers_general NVS
$145.41
price up icon 2.73%
drug_manufacturers_general MRK
$108.89
price up icon 0.66%
drug_manufacturers_general NVO
$58.88
price down icon 1.22%
Cap:     |  Volume (24h):